LENZ
MaterialsLENZ Therapeutics Inc
$9.68+0.61 (+6.73%)PRE
Live · NASDAQ · May 8, Close
AI Insight
What's Moving LENZ Today?
No stock-specific AI insight has been generated for LENZ yet. Check back soon — insights are generated from recent news analysis.
Fundamentals
Market Cap$304M
P/E Ratio—
EPS—
Dividend Yield—
Dividend / Share—
ROE—
Profit Margin—
Debt / Equity—
Trading
Volume1.1M
Avg Volume (10D)—
Shares Outstanding31.4M
LENZ News
19 articles- LENZ Therapeutics to Report First Quarter 2026 Financial Results and Recent Corporate Highlights on May 11, 2026 and Attend Upcoming Investor ConferenceYahoo Finance·May 4, 2026
- LENZ Therapeutics Announces Submission of Marketing Authorization Application to the Medicines and Healthcare products Regulatory Agency for VIZZ® for the Treatment of Presbyopia in the United KingdomYahoo Finance·Apr 20, 2026
- President of LENZ Therapeutics Picks Up 57% More StockYahoo Finance·Apr 1, 2026
- The Consensus EPS Estimates For LENZ Therapeutics, Inc. (NASDAQ:LENZ) Just Fell DramaticallyYahoo Finance·Mar 29, 2026
- Why Lenz Therapeutics Stock Plummeted by Almost 20% This WeekMotley Fool·Mar 27, 2026
- LENZ Therapeutics, Inc. Q4 2025 Earnings Call SummaryMoby·Mar 25, 2026
- LENZ Therapeutics Inc (LENZ) Q4 2025 Earnings Call Highlights: Strong Cash Position and ...Yahoo Finance·Mar 24, 2026
- LENZ Therapeutics Q4 Earnings Call HighlightsMarketbeat·Mar 24, 2026
- Why Lenz Therapeutics Stock Crashed TodayMotley Fool·Mar 24, 2026
- LENZ Therapeutics, Inc. (LENZ) Reports Q4 Loss, Misses Revenue EstimatesYahoo Finance·Mar 24, 2026
- LENZ Therapeutics Reports Fourth Quarter and Full Year 2025 Financial Results and Recent Corporate HighlightsYahoo Finance·Mar 24, 2026
- LENZ Therapeutics to Report Fourth Quarter and Full Year 2025 Financial Results and Recent Corporate Highlights on March 24, 2026Yahoo Finance·Mar 17, 2026
- LENZ Therapeutics Announces Submission of Marketing Authorization Application to European Medicines Agency for VIZZ® for the Treatment of PresbyopiaYahoo Finance·Mar 10, 2026
- LENZ Therapeutics to Present at Upcoming Investor ConferencesYahoo Finance·Feb 23, 2026
- LENZ Therapeutics and Sarah Jessica Parker announce the launch of “Make it VIZZable”, the VIZZ consumer campaignYahoo Finance·Jan 14, 2026
- A Look At LENZ Therapeutics (LENZ) Valuation After VIZZ Launch Momentum And New Lunatus AgreementYahoo Finance·Jan 13, 2026
- LENZ Therapeutics (LENZ) Is Down 7.1% After VIZZ Middle East Deal And Early Launch Data - Has The Bull Case Changed?Yahoo Finance·Jan 12, 2026
- Analysts Expect Breakeven For LENZ Therapeutics, Inc. (NASDAQ:LENZ) Before LongYahoo Finance·Jan 8, 2026
- LENZ Therapeutics Reports Fourth Quarter 2025 Preliminary Unaudited Financial Results and Recent Corporate UpdatesYahoo Finance·Jan 7, 2026
All 19 articles loaded
Price Data
Open$9.22
Previous Close$9.07
Day High$9.78
Day Low$8.92
52 Week High—
52 Week Low—
Fundamentals
Market Cap$304M
P/E Ratio—
EPS—
Dividend Yield—
Dividend / Share—
ROE—
Profit Margin—
Debt / Equity—
Trading
Volume1.1M
Avg Volume (10D)—
Shares Outstanding31.4M
About LENZ Therapeutics Inc
LENZ Therapeutics Inc is a late-stage biopharmaceutical company focused on developing and commercializing therapies to improve vision and developing ophthalmic pharmaceutical products. Its products VIZZ (aceclidine ophthalmic solution) 1.44% is a once-daily eye drop developed to restore clear near vision for up to 10 hours. VIZZ is powered by aceclidine, highlighted by its differentiated mechanism of action as a predominantly pupil-selective miotic that interacts with the iris, with minimal ciliary muscle stimulation.
MaterialsBIOLOGICAL PRODUCTS, (NO DIAGNOSTIC SUBSTANCES)
Company Details
Security TypeStock
ExchangeNASDAQ
Currency—
Round Lot—
SICBIOLOGICAL PRODUCTS, (NO DIAGNOSTIC SUBSTANCES)
CIK—
Composite FIGI—
Share Class FIGI—